AstraZeneca PLC (AZN)

35.07
0.29 0.82
NYSE : Health Care
Prev Close 35.36
Open 35.21
Day Low/High 34.94 / 35.25
52 Wk Low/High 25.55 / 35.60
Volume 3.13M
Avg Volume 3.98M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 88.32B
EPS 1.40
P/E Ratio 15.64
Div & Yield 1.90 (5.40%)

Latest News

Europe Benchmarks Rebound as Central Bank Actions Fall by the Wayside

Europe Benchmarks Rebound as Central Bank Actions Fall by the Wayside

European stocks rebounded with a bang Friday as recent central bank actions fell by the wayside and markets took heart from the latest bailout deal between Greece and the EU.

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

AstraZeneca Presents New Data Underpinning Safety Profile And Real-World CV Outcomes Of Farxiga At ADA 2017

AstraZeneca presented new data at the American Diabetes Association's (ADA) 77th Scientific Sessions underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

AstraZeneca To Present Scientific Advances In Cardiovascular And Metabolic Diseases At 2017 ADA Scientific Sessions

AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company's Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga...

AstraZeneca Presents Tagrisso® (osimertinib) Data In Patients With EGFR T790M-Mutation Positive Lung Cancer And Central Nervous System Metastases

AstraZeneca today reported further evidence that Tagrisso ® (osimertinib), the potential new standard of care for patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small...

European Stocks Slip as Banks, Economic Data Weigh

European Stocks Slip as Banks, Economic Data Weigh

European stocks slipped Monday as investors digested the latest terror attack in the U.K., continued concern over Spanish banks and a series of poorer-than-expected economic bulletins.

AstraZeneca's Big Bet on Oncology May Finally Pay Off

AstraZeneca's Big Bet on Oncology May Finally Pay Off

AstraZeneca plc said Monday that one of its new drugs has proven more effective than chemotherapy in treating a certain type of breast cancer.

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

Wake Up Wall Street: U.K. Prime Minister Theresa May Takes on Tech Companies

U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.

LYNPARZA™ (olaparib) Significantly Reduces The Risk Of Disease Worsening Or Death In Patients With BRCA-Mutated Metastatic Breast Cancer

AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with...

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump

Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.

AstraZeneca Delivers New Data On Expanding Portfolio Of Cancer Medicines At 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company's science-led strategy for transformational cancer medicine development at...

BRILINTA 90mg (Photo: Business Wire)

AstraZeneca today announced that the Company is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA ®...

Blackberry, Exact Sciences, Splunk, Freeport-McMoRan: 'Mad Money' Lightning Round

Blackberry, Exact Sciences, Splunk, Freeport-McMoRan: 'Mad Money' Lightning Round

Jim Cramer focuses on Blackberry, Exact Sciences, Splunk, Freeport-McMoRan and more.

BYDUREON EXSCEL Trial Meets Primary Safety Objective In Type-2 Diabetes Patients At Wide Range Of Cardiovascular Risk

AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL ( EX enatide S tudy of C ardiovascular E vent L owering) trial.

Get Your Head Into the Cloud: Cramer's 'Mad Money' Recap (Monday 5/22/17)

Get Your Head Into the Cloud: Cramer's 'Mad Money' Recap (Monday 5/22/17)

Jim Cramer says it's more than just the cloud. There are some astounding moves in the broader tech sector, too.

AstraZeneca Shares Rise as Investors Shrug Off Mixed Diabetes Results

AstraZeneca Shares Rise as Investors Shrug Off Mixed Diabetes Results

AstraZeneca shares edged higher Tuesday as investors shrugged off a mixed set of phase-3 results for the Anglo Swedish drug maker's Bydureon Exscel type II diabetes treatment.

Phase III ZONDA Trial For Benralizumab Shows Ability To Reduce Oral Steroid Use In Severe Asthma Patients

Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to...

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

GlaxoSmithKline Could Buy Out Partner Novartis

GlaxoSmithKline Could Buy Out Partner Novartis

Novartis holds a 36.5% stake in the healthcare company.

Wall Street Mixed as Rash of Weak Retail Earnings Continues

Wall Street Mixed as Rash of Weak Retail Earnings Continues

Wall Street hold mixed through to the close Friday after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.

S&P 500, Dow Decline After Retail Sales Rebound Buoys Rate-Hike Odds

S&P 500, Dow Decline After Retail Sales Rebound Buoys Rate-Hike Odds

Stocks held mostly lower on Friday as better-than-expected numbers on U.S. retail sales put a June rate hike on the markets' radar.

Stocks Hold Lower as Retail Sales, CPI Support June Rate Hike

Stocks Hold Lower as Retail Sales, CPI Support June Rate Hike

Stocks held lower on Friday even after better-than-expected numbers on U.S. retail sales and consumer prices.

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of "frustration".

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures are slipping Friday ahead of data on consumer prices and retail sales and after the U.S. and China reach a trade deal.

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?